

1 Occult obstructive coronary artery disease is associated with prolonged 2 cardiac troponin elevation following strenuous exercise

3
4 Øyunn Kleiven MD^a, Torbjørn Omland MD, PhD^b, Øyvind Skadberg MD^c, Tor Harald
5 Melberg MD, PhD^a, Magnus Friestad Bjørkavoll-Bergseth MD^a, Bjørn Auestad PhD^{d,e}, Rolf
6 Bergseth MD^f, Ole Jakob Greve MD^g, Kristin Moberg Aakre MD, PhD^{h,i,j}, Stein Ørn MD,
7 PhD^{a,k}

8
9 ^a Cardiology Department, Stavanger University Hospital, Stavanger, Norway.

10 ^b Division of Medicine, Akershus University Hospital, and University of Oslo, Oslo, Norway

11 ^c Department of Biochemistry, Stavanger University Hospital, Stavanger, Norway.

12 ^d Department of Research, Stavanger University Hospital, Stavanger, Norway.

13 ^e Department of Mathematics and Physics, University of Stavanger, Norway.

14 ^f Klepp Municipality, Kleppe, Norway

15 ^g Department of Radiology, Stavanger University Hospital, Stavanger, Norway.

16 ^h Department of Medical Biochemistry and Pharmacology, Haukeland University Hospital, Bergen, Norway

17 ⁱ Hormone Laboratory, Haukeland University Hospital, Bergen, Norway

18 ^j Department of Clinical Science, University of Bergen, Bergen, Norway

19 ^k Department of Electrical Engineering and Computer Science, University of Stavanger, Stavanger, Norway

20
21 **Author contributions:** ØK, TO, ØS, TM and SØ contributed to conception and design. All
22 authors contributed to data acquisition and/or analysis and interpretation. ØK and SØ drafted
23 the manuscript. All authors critically revised the manuscript, gave final approval and agree to
24 be accountable for all aspects of the work ensuring integrity and accuracy.

25
26 **Funding:** This work was supported by an operating grant from the North Sea Race
27 (“Nordsjørittet”), Abbott Diagnostics (Abbott Diagnostics, IL, USA), the Laerdal Foundation
28 (Stavanger, Norway), and Stavanger University Hospital and research grants from the
29 Norwegian Health Association (Oslo, Norway).

30
31 **Conflict of Interest:** ØK, MB, TM, TA, BA, OJG, and SØ have no conflicts of interest to
32 declare. The following modest conflicts of interest have been reported by ØS, KMA, RB, and
33 TO. ØS has received lecture fees from Abbott Diagnostics. KMA has served on one advisory
34 board for Roche Diagnostics. RB is a board member of the North Sea Race organization. TO
35 has served on advisory boards for Abbott Diagnostics and Roche Diagnostics, and has
36 received research support from Abbott Diagnostics and Roche Diagnostics, via Akershus
37 University Hospital, and speaker’s honoraria from Roche Diagnostics.

38
39 **Corresponding author:** Øyunn Kleiven MD, Stavanger University Hospital, PO 8400, 4068
40 Stavanger, Norway, Telephone: + 47 93 85 94 40. E-mail: oyunn.kleiven@sus.no

41
42 **Word count:** 3404 (Introduction to References) + 4 Figures (1000) + 2 Tables (500) = 4904

43
44 **Acknowledgements:** We thank the participants and the medical staff at Stavanger University
45 Hospital who contributed to the data acquisition, including doctors C. Manhenke and N.
46 Bogale. A special thanks to T. Aarsland, J. Selvåg, and J.M. Nilsen for their contributions to
47 the planning and implementation of this study. We also thank T. Svihus and J. Havnen for
48 organizing and evaluating the CCTA examinations.

1 **Abstract**

2 **Background:** Sudden cardiac death among middle-aged recreational athletes is
3 predominantly due to myocardial ischemia. This study examined if measuring cardiac
4 troponin I and T (cTnI and cTnT) after strenuous exercise could identify occult obstructive
5 coronary artery disease (CAD).

6 **Design:** Prospective observational study

7 **Methods:** Subjects were recruited from 1002 asymptomatic recreational cyclists completing a
8 91-km mountain bike race (North Sea Race Endurance Exercise Study). No subject had
9 known cardiovascular disease or took cardiovascular medication. Blood samples were
10 collected within 24 h before and 3 and 24 h after the race. Coronary computed tomography
11 angiography (CCTA) was performed in 80 participants with the highest post-exercise cTnI
12 and in 40 reference subjects with moderately elevated cTnI values.

13 **Results:** Study subjects (n=120) were 45 (36-52) years old and 74% were male. There were
14 similar demographics in the High-cTnI and the Reference group. The cTn concentrations were
15 highest at 3 h post-race: cTnI, 224 (125-304) ng/L; cTnT, 89 (55-124) ng/L. Nine subjects had
16 obstructive CAD on CCTA, eight of whom were High-cTnI responders. Two subjects had
17 myocardial bridging, both High-cTnI responders. Troponin concentrations at 24 h post-race
18 were higher in subjects with obstructive CAD than the rest of the cohort (n=109): cTnI, 151
19 (72-233) ng/L vs. 24 (19-82) ng/L, p=0.005; cTnT, 39 (25-55) ng/L vs. 20 (14-31) ng/L,
20 p=0.002. The ROC-AUCs for predicting obstructive CAD were 0.79, p=0.005 (cTnI) and
21 0.82, p=0.002 (cTnT).

22 **Conclusion:** In subjects with occult obstructive CAD there was a prolonged elevation of cTn
23 following strenuous exercise.

24 Abstract word-count: 245

1

2 **Key-words:** Exercise-induced troponin, recreational sport, exercise, coronary artery disease.

3 Trial registration number: NCT02166216 <https://clinicaltrials.gov/ct2/show/NCT02166216>

4

5

1 **Introduction**

2 Myocardial ischemia is the major cause of sports-related sudden cardiac death in recreational
3 athletes ≥ 35 years of age ^{1 2}. Most individuals suffering from sports-related sudden cardiac
4 death are asymptomatic or fail to recognize warning symptoms prior to the event ³. Therefore,
5 the identification of these subjects is challenging. Elevated resting cardiac troponin (cTn)
6 levels are associated with an increased risk of an adverse cardiovascular (CV) event ⁴⁻⁶. Thus,
7 it is reasonable to assume that exercise-induced cTn levels may be used to evaluate CV risk
8 during exercise. However, following strenuous physical exercise, there is a physiological
9 increase in cTn levels in healthy individuals ⁷⁻¹¹. This physiological increase may mask a
10 pathological response and preclude the use of exercise-induced cTn elevation as a risk
11 marker. Thus, the clinical interpretation of post-exercise cTn levels is problematic.

12 Recently, we published a pilot study demonstrating that the highest exercise-induced
13 cTn levels were present in asymptomatic subjects with obstructive coronary artery disease
14 (CAD) ¹². However, only 13 subjects were assessed by coronary computed tomography
15 angiography (CCTA) in that study. The present study explores the potential diagnostic role of
16 cTn assessment following strenuous exercise in a larger subset of presumably healthy
17 individuals included in the North Sea Race Endurance Exercise Study 2014 ¹³. The main aim
18 of the present study was to compare the exercise-induced cTn profiles in presumably healthy
19 recreational cyclists with and without coronary artery obstruction identified by CCTA.

20
21
22

1 **Methods**

2 **Design and study population**

3 The current study used CCTA to identify obstructive CAD in a subset of 120 subjects
4 participating in the NEEDED 2014 main-study (n=1002)¹³. All study participants were
5 asymptomatic, recreational cyclists participating in the 91-km North Sea mountain bike race.
6 Screening and patient inclusion are presented in Figure 1. Inclusion and exclusion criteria
7 have been reported previously¹³. Blood samples, clinical assessments, blood pressure
8 measurements, and ECGs were obtained the day before (baseline) and at 3 and 24 h following
9 the race. The study complied with the Declaration of Helsinki and was approved by the
10 Regional Ethics Committee (REK 2013/550). All participants signed informed consent forms
11 prior to enrollment into the study.

12 **Selection of subjects for coronary computed tomography angiography**

13 Study subjects were selected for the present sub-study based upon their maximal cardiac
14 troponin I (cTnI) value following the race. Two different subcohorts were studied. The first
15 cohort (High-cTnI group) consisted of the 80 subjects with the highest cTnI values (from the
16 total NEEDED 2014 population, n=1002) at any time-point following the race. This cohort
17 was assessed by CCTA within a few weeks following the race. The second cohort consisted
18 of a Reference group of 40 subjects with maximal cTnI values that reflected the values of the
19 remaining NEEDED 2014 population (n=922). The reference population selection was based
20 on a representative 20/80% (Female/Male) sex-distribution, with each subject matched from
21 the NEEDED 2014 population according to age. The reference group was assessed by CCTA
22 within a year following the race.

1 **Blood samples**

2 Venous blood samples were drawn from the antecubital vein at baseline and at 3 and 24 h
3 after the race. Cardiac TnI (serum) was analyzed within 24 h at Stavanger University Hospital
4 on an Architect i2000SR using the high-sensitive cTnI STAT assay, which has a lower limit
5 of detection of 1.6 ng/L and a 99th percentile of 26 ng/L (Abbott Diagnostics, IL USA) ¹⁴.
6 Serum was frozen at -80 °C until thawed and analyzed for cardiac troponin T (cTnT) on a
7 Cobas e601; this assay has a limit of blank of 3 ng/L and a 99th percentile of 14 ng/L (Roche
8 Diagnostics, Switzerland) ¹⁴.

9 **Coronary computed tomography angiography**

10 Coronary calcification and CCTA were obtained using a Siemens Somatom Definition Flash
11 Dual Source. Obstructive CAD was defined as $\geq 50\%$ luminal stenosis in the left coronary
12 artery, the right coronary artery, the circumflex artery, or a diagonal or marginal branch. The
13 CCTA examinations were independently assessed by two experienced radiologists, blinded to
14 the cTn findings. Non-obstructive CAD was defined as a luminal narrowing of 1-50%.
15 Subjects with obstructive CAD on CCTA were referred for conventional coronary
16 angiography and treated with percutaneous coronary intervention or coronary artery bypass
17 grafting, as determined by the cardiologist performing the angiography.

18 **Statistical analysis**

19 Normally distributed continuous variables are reported as the mean \pm SD, while continuous
20 variables with markedly skewed distributions are reported as the median and interquartile
21 range (25th percentile-75th percentile). The Shapiro-Wilk test was used to test for normality.
22 The Chi-Square test, Fisher's Exact test, Student t-test, or Mann-Whitney U test was used for
23 comparison of groups, as appropriate. A two-tailed p-value < 0.05 was considered significant.
24 For statistical analyses, the statistical software programs SPSS version 24, "R", and GraphPad
25 Prism 7 were used.

1
2
3

1 **Results**

2 Participants were 45.4 (36.3-52.3) years old and 74.2% were male. The race duration was 3.6
3 (3.4-4.1) h. Subjects in the High-cTnI and the Reference groups had similar ages, gender and
4 body mass indexes (Table 1). None of the subjects reported CV symptoms during or
5 following the race. The CCTA identified nine subjects with obstructive CAD, who all had
6 normal ECGs at baseline and 3 h after the race. However, at 24 h following the race, two
7 subjects had new T-wave inversions (V2/V4-6) and one had high precordial T-waves. Two
8 subjects in the High-cTnI group had myocardial bridging, and were excluded from the
9 analysis due to the uncertain clinical implication of this finding. Their characteristics are,
10 however, included in Table 2.

11 **Troponin profiles**

12 High-cTnI subjects had maximum cTnI concentration after the race ranging from 196-7919
13 ng/L (Supplementary Figure 1). Most High-cTnI subjects achieved maximum cTnI values at
14 3h following the race (n=78, 97.5%). The Reference group had a maximum cTnI range of 7-
15 189 ng/L (Supplementary Figure 1). All Reference group subjects achieved maximum cTnI
16 concentrations at 3 h following the race. Overall, cTnI concentrations increased markedly
17 from baseline (2.7 [1.6-6.9] ng/L) to 3 h after the race (224 [125-304] ng/L), declining at 24 h
18 after the race (39 [19-102] ng/L). Similarly, cTnT increased from baseline (3.1 [3.0-5.1] ng/L)
19 to 3 h after the race (89 [55-124] ng/L), followed by a decline at 24 h after the race (23 [15-
20 38] ng/L). The cTnI values exceeded the 99th percentile (26 ng/L) in 95.8% of study subjects
21 at 3 h and 63.3% at 24 h following the race. The cTnT values exceeded the 99th percentile (14
22 ng/L) in 98.3% of study subjects at 3 h, and 75.8% at 24 h following the race.

1 **Coronary computed tomography angiography findings**

2 In total, 80 of the 120 subjects (67 %) had normal coronary arteries, two had myocardial
3 bridging (1.7 %), and 39 had CAD (32.5 %, this number includes one subject who also had
4 myocardial bridging, Figure 2). Non-obstructive CAD was present in 15 subjects in the High-
5 cTnI group (18.8 %), including one with myocardial bridging, and in 15 subjects (37.5 %) in
6 the Reference group. A total of eight subjects (10.0%) had obstructive CAD in the High-cTnI
7 group; whereas, one subject (2.5%) had obstructive CAD in the Reference group.

8 The median CAC score of the High-cTnI group was 0 (0-0) Agatston Units, vs 0 (0-11)
9 Agatston Units in the Reference group, p=0.132. When only subjects with CAD were
10 assessed, the CAC scores were 36 (2-187) Agatston Units in the High-cTnI group vs 18 (4-
11 71) Agatston Units in the Reference group, p=0.72. One subject (Subject F) was only imaged
12 by conventional coronary angiography and was not included in this analysis.

13 The odds ratio (OR) for obstructive CAD between the two cohorts was: 4.46 (95% CI: 0.54-
14 37.0), p=0.17.

15 **Troponin concentrations in relation to coronary anatomy and pathology**

16 Both cTnI and cTnT levels were significantly higher 24 h following the race in subjects with
17 obstructive CAD compared with the rest of the cohort (Figure 3, Supplementary Table 1):

18 cTnI: p=0.005, cTnT: p=0.002 (n=118). There was no between-group difference in the cTn
19 values at baseline or at 3 h following the race. Within the High-cTnI group, subjects with
20 obstructive CAD (n=8) still had significantly higher cTn values at 24 h after the race than the
21 rest of the group (cTnI: p=0.006, cTnT: p=0.004, Supplementary Table 2).

22 Only cTn values at 24 h after the race significantly predicted the presence of obstructive
23 CAD: cTnI: area under the curve (AUC) of 0.78, p=0.005; cTnT: 0.82, p=0.002 (Figure 4).

24

1 **Discussion**

2 This study has several novel and important findings: First, both cTnI and cTnT levels were
3 significantly higher 24 h following the race in subjects with obstructive CAD compared with
4 those without coronary artery obstruction. Second, there was no difference in cTn levels
5 between subjects with and without coronary artery obstruction prior to or 3 h following the
6 race. Third, none of the subjects with obstructive CAD reported symptoms suggestive of CAD
7 during or following the race. Our findings are in line with the pilot study but add to previous
8 data suggesting that subjects with obstructive CAD have a different cTn profile than the
9 physiological cTn response, with a prolonged cTn release resembling an ischemic injury
10 pattern. These findings, however, need to be confirmed by future studies before they can be
11 used in a clinical context.

12

13 **Troponin profiles in subjects with and without obstructive CAD**

14 A total of nine subjects with obstructive CAD were identified in the present study, eight of
15 whom were in the High-cTn group (Table 2). Additionally, two persons with myocardial
16 bridging, both in the High-cTn group, were excluded from the analysis due to the unclear
17 implications of this characteristic in this setting (23). Physiological exercise-induced cTn
18 elevation is thought to be due to increased myocardial stress generating a leakage of loosely
19 bound cTn into the blood stream by cytoplasmic blebbing, release of microparticles, increased
20 membrane permeability, or activation of apoptosis of cardiomyocytes ^{11, 15, 16}. Exercise-
21 induced cTn elevation peaks at 3-6 h (cTnI) and 2-5 h (cTnT) following exercise ^{11, 17, 18}.
22 These peaks differ from the later rise in cTn levels following myocardial infarction. After
23 myocardial infarction, there is a release of structural cTn due to cellular necrosis, with a rapid
24 increase in cTn levels, reaching maximum values 11-12 h following revascularization ^{19, 20}.

1 The later peak in cTn levels following myocardial infarction reflects a slower release of
2 structural cTn due to destruction of cellular components and a prolonged washout²⁰. In the
3 present study, the prolonged elevation of cTn levels in subjects with obstructive CAD may
4 suggest a different mechanism of cTn release than the short-term physiological cTn response.
5 Although no additional determination of myocardial ischemia was performed in the present
6 study, it is possible that the prolonged cTn elevation following exercise in subjects with
7 obstructive CAD is due to the development of demand ischemia during exercise. This is in
8 line with the findings of Kim et al. who found demand ischemia to be the most frequent
9 mechanism of sport-related sudden cardiac arrest²¹. This important finding warrants further
10 investigation into the relationship between demand ischemia and the cTn response following
11 strenuous exercise.

12 **The absence of ischemic symptoms during strenuous exercise**

13 Preventing deaths due to myocardial ischemia in recreational athletes is challenging, both due
14 to the low event rate and the frequent lack of recognizable warning symptoms prior to the
15 event^{3, 22, 23}. In the study by Smallmann et al., only 17 % of subjects > 35 years of age who
16 suffered a sport-related cardiac death had reported chest pain in the 6 months leading up to the
17 event, despite the fact that most of these deaths were attributed to atherosclerotic heart
18 disease².

19 During strenuous exercise, there are alterations in pain perception that may suppress
20 symptoms and preclude an early clinical diagnosis²⁴⁻²⁶. In the present study, none of the
21 subjects reported chest pain during the consultation with the cardiologists at 3 or 24 hours
22 following the race. At 24 hours after the race, Subject F had new T-wave inversions in leads V2-3
23 and highly elevated cTnI. He was admitted to hospital for a conventional coronary angiography
24 and during the hospitalization he retrospectively reported some chest discomfort during the race,

1 despite having finished the race faster than expected. His case underscores the challenges related
2 to the symptom-based CV evaluation strategy of athletes.

3 **The use of regular training or competitive events to determine the risk of demand** 4 **ischemia**

5 Most previous studies have not been able to demonstrate a significant difference in the cTn
6 response between subjects with and without evidence of ischemia using standardized stress-
7 or perfusion tests ^{27,28}. During prolonged strenuous exercise, there are major changes in
8 hemodynamics, neuro-endocrine activation, acid-base status, and metabolism that may induce
9 demand ischemia ^{21,29}. These factors are not addressed by current routine exercise or stress
10 tests that are mostly of short duration with limited exposure to high intensity work. The
11 present study suggests there is diagnostic potential for using field-data in the detection of
12 obstructive CAD in asymptomatic individuals. Recreational athletes perform numerous
13 sessions of prolonged, high-intensity exercise both during training and competitive events that
14 may be used to evaluate risk. During these sessions, athletes are exposed to far more vigorous
15 exercise than in traditional stress tests assessing ischemia. Also, repeated assessments of the
16 exercised-induced cTn response in connection with exercise sessions may lead to personal
17 exercise cTn profiles that may be used to monitor the athlete.

18 A major challenge in the use of real-life data is the need for sufficiently accurate
19 quantification of the amount physical work performed. Future studies need to clarify the
20 relationship between exercise-induced cTn release and exercise intensity and duration by
21 direct measurement of work. Failure to perform enough work to induce demand ischemia may
22 possibly explain the low 24 h cTn levels of subject C and I in the present study (Table 2).

1 **Limitations**

2 For logistic reasons, it was only possible to examine 80 individuals with CCTA within the
3 first weeks following the race. The 40 subjects in the Reference population were examined
4 later. There was one subject with obstructive CAD in the Reference population (Subject C).
5 Due to the late CCTA assessment of this subject (almost a year following the race), it is not
6 possible to determine if the coronary artery stenosis was present at the time of the race.

7 Due to logistic challenges with the large sample size of the original study (n=1002), blood
8 sampling was limited to 24 h before and 3 and 24 h after the race.

9 Long-term follow-up is needed in order to assess the association between exercise-induced
10 cTn elevation and future CV events. Follow-up studies are planned for the entire NEEDED
11 2014 cohort (n=1002) at 5, 10 and 20 years after the race to determine the long-term
12 prognostic role for prolonged cTn elevation. The results of this study need to be confirmed by
13 future studies before specific recommendations regarding the clinical use of exercise-induced
14 troponin elevation can be made.

15

16 **Conclusion**

17 In this prospective observational study, cTn levels 24 h after strenuous exercise were higher in
18 asymptomatic subjects with obstructive CAD compared with subjects with no coronary artery
19 obstruction. The diagnostic role of delayed post-exercise cTn elevation remains to be
20 determined in future studies.

21

22

23

24

25

26

27

28


1 **References**

- 2 1. Marijon E, Uy-Evanado A, Reinier K, et al. Sudden cardiac arrest during sports
3 activity in middle age. *Circulation* 2015; 131: 1384-1391. 2015/04/08. DOI:
4 10.1161/circulationaha.114.011988.
- 5 2. Smallman DP, Webber BJ, Mazuchowski EL, et al. Sudden cardiac death associated
6 with physical exertion in the US military, 2005-2010. *British journal of sports medicine* 2016;
7 50: 118-123. 2015/11/28. DOI: 10.1136/bjsports-2015-094900.
- 8 3. Marijon E, Tafflet M, Celermajer DS, et al. Sports-related sudden death in the general
9 population. *Circulation* 2011; 124: 672-681. 2011/07/27. DOI:
10 10.1161/circulationaha.110.008979.
- 11 4. Omland T, de Lemos JA, Sabatine MS, et al. A sensitive cardiac troponin T assay in
12 stable coronary artery disease. *The New England journal of medicine* 2009; 361: 2538-2547.
13 2009/11/27. DOI: 10.1056/NEJMoa0805299.
- 14 5. Willeit P, Welsh P, Evans JDW, et al. High-Sensitivity Cardiac Troponin
15 Concentration and Risk of First-Ever Cardiovascular Outcomes in 154,052 Participants.
16 *Journal of the American College of Cardiology* 2017; 70: 558-568. 2017/07/29. DOI:
17 10.1016/j.jacc.2017.05.062.
- 18 6. Omland T, de Lemos JA, Holmen OL, et al. Impact of sex on the prognostic value of
19 high-sensitivity cardiac troponin I in the general population: the HUNT study. *Clinical*
20 *chemistry* 2015; 61: 646-656. 2015/02/20. DOI: 10.1373/clinchem.2014.234369.
- 21 7. Scherr J, Braun S, Schuster T, et al. 72-h kinetics of high-sensitive troponin T and
22 inflammatory markers after marathon. *Medicine and science in sports and exercise* 2011; 43:
23 1819-1827. 2011/03/31. DOI: 10.1249/MSS.0b013e31821b12eb.
- 24 8. Fortescue EB, Shin AY, Greenes DS, et al. Cardiac troponin increases among runners
25 in the Boston Marathon. *Annals of emergency medicine* 2007; 49: 137-143, 143.e131.
26 2006/12/06. DOI: 10.1016/j.annemergmed.2006.09.024.
- 27 9. Mousavi N, Czarnecki A, Kumar K, et al. Relation of biomarkers and cardiac
28 magnetic resonance imaging after marathon running. *The American journal of cardiology*
29 2009; 103: 1467-1472. 2009/05/12. DOI: 10.1016/j.amjcard.2009.01.294.
- 30 10. Shave R, George KP, Atkinson G, et al. Exercise-induced cardiac troponin T release: a
31 meta-analysis. *Medicine and science in sports and exercise* 2007; 39: 2099-2106. 2007/11/30.
32 DOI: 10.1249/mss.0b013e318153ff78.
- 33 11. Gresslien T and Agewall S. Troponin and exercise. *International journal of cardiology*
34 2016; 221: 609-621. 2016/07/16. DOI: 10.1016/j.ijcard.2016.06.243.
- 35 12. Skadberg O, Kleiven O, Bjorkavoll-Bergseth M, et al. Highly increased Troponin I
36 levels following high-intensity endurance cycling may detect subclinical coronary artery
37 disease in presumably healthy leisure sport cyclists: The North Sea Race Endurance Exercise
38 Study (NEEDED) 2013. *European journal of preventive cardiology* 2017; 24: 885-894.
39 2017/02/12. DOI: 10.1177/2047487317693130.
- 40 13. Kleiven O, Omland T, Skadberg O, et al. Race duration and blood pressure are major
41 predictors of exercise-induced cardiac troponin elevation. *International journal of cardiology*
42 2019. DOI: 10.1016/j.ijcard.2019.02.044.
- 43 14. Ungerer JP, Tate JR and Pretorius CJ. Discordance with 3 Cardiac Troponin I and T
44 Assays: Implications for the 99th Percentile Cutoff. *Clinical chemistry* 2016; 62: 1106-1114.
45 2016/06/24. DOI: 10.1373/clinchem.2016.255281.
- 46 15. Weil BR, Suzuki G, Young RF, et al. Troponin Release and Reversible Left
47 Ventricular Dysfunction After Transient Pressure Overload. *Journal of the American College*
48 *of Cardiology* 2018; 71: 2906-2916. 2018/06/23. DOI: 10.1016/j.jacc.2018.04.029.

- 1 16. Mair J, Lindahl B, Hammarsten O, et al. How is cardiac troponin released from injured
2 myocardium? *European heart journal Acute cardiovascular care* 2017; 2048872617748553.
3 2017/12/28. DOI: 10.1177/2048872617748553.
- 4 17. Middleton N, George K, Whyte G, et al. Cardiac troponin T release is stimulated by
5 endurance exercise in healthy humans. *Journal of the American College of Cardiology* 2008;
6 52: 1813-1814. 2008/11/22. DOI: 10.1016/j.jacc.2008.03.069.
- 7 18. Skadberg O, Kleiven O, Orn S, et al. The cardiac troponin response following physical
8 exercise in relation to biomarker criteria for acute myocardial infarction; the North Sea Race
9 Endurance Exercise Study (NEEDED) 2013. *Clinica chimica acta; international journal of*
10 *clinical chemistry* 2018; 479: 155-159. 2018/01/26. DOI: 10.1016/j.cca.2018.01.033.
- 11 19. Laugaudin G, Kuster N, Petiton A, et al. Kinetics of high-sensitivity cardiac troponin
12 T and I differ in patients with ST-segment elevation myocardial infarction treated by primary
13 coronary intervention. *European heart journal Acute cardiovascular care* 2016; 5: 354-363.
14 2015/05/07. DOI: 10.1177/2048872615585518.
- 15 20. Orn S, Manhenke C, Greve OJ, et al. Microvascular obstruction is a major determinant
16 of infarct healing and subsequent left ventricular remodelling following primary percutaneous
17 coronary intervention. *European heart journal* 2009; 30: 1978-1985. 2009/06/09. DOI:
18 10.1093/eurheartj/ehp219.
- 19 21. Kim JH, Malhotra R, Chiampas G, et al. Cardiac arrest during long-distance running
20 races. *The New England journal of medicine* 2012; 366: 130-140. 2012/01/13. DOI:
21 10.1056/NEJMoal106468.
- 22 22. Gutterman DD. Silent myocardial ischemia. *Circulation journal : official journal of*
23 *the Japanese Circulation Society* 2009; 73: 785-797. 2009/03/14.
- 24 23. Sharma B, Asinger R, Francis GS, et al. Demonstration of exercise-induced painless
25 myocardial ischemia in survivors of out-of-hospital ventricular fibrillation. *The American*
26 *journal of cardiology* 1987; 59: 740-745. 1987/04/01.
- 27 24. Flood A, Waddington G, Thompson K, et al. Increased conditioned pain modulation in
28 athletes. *Journal of sports sciences* 2017; 35: 1066-1072. 2016/07/28. DOI:
29 10.1080/02640414.2016.1210196.
- 30 25. Geva N and Defrin R. Enhanced pain modulation among triathletes: a possible
31 explanation for their exceptional capabilities. *Pain* 2013; 154: 2317-2323. 2013/06/29. DOI:
32 10.1016/j.pain.2013.06.031.
- 33 26. Lima LV, Abner TSS and Sluka KA. Does exercise increase or decrease pain? Central
34 mechanisms underlying these two phenomena. *The Journal of physiology* 2017; 595: 4141-
35 4150. 2017/04/04. DOI: 10.1113/jp273355.
- 36 27. Rosjo H, Kravdal G, Hoiseth AD, et al. Troponin I measured by a high-sensitivity
37 assay in patients with suspected reversible myocardial ischemia: data from the Akershus
38 Cardiac Examination (ACE) 1 study. *Clinical chemistry* 2012; 58: 1565-1573. 2012/09/22.
39 DOI: 10.1373/clinchem.2012.190868.
- 40 28. Lee G, Twerenbold R, Tanglay Y, et al. Clinical benefit of high-sensitivity cardiac
41 troponin I in the detection of exercise-induced myocardial ischemia. *American heart journal*
42 2016; 173: 8-17. 2016/02/28. DOI: 10.1016/j.ahj.2015.11.010.
- 43 29. Predel HG. Marathon run: cardiovascular adaptation and cardiovascular risk.
44 *European heart journal* 2014; 35: 3091-3098. 2014/01/11. DOI: 10.1093/eurheartj/ehf502.
45

1 **Figure 1**


2 Study recruitment and flow; CAD = coronary artery disease, CCTA = coronary computed
3 tomography angiography, CV = cardiovascular, STEMI = ST-segment elevation myocardial
4 infarction.



5
6

1 **Figure 2**

2 Illustration of a) normal coronary arteries on coronary computed tomography angiography
3 (CCTA), b) myocardial bridging of the left anterior descending artery on CCTA (Subject A),
4 c) obstructive CAD of the right coronary artery on conventional angiography (Subject E), d)
5 non-obstructive CAD of the left anterior descending artery on CCTA (small white spot in the
6 proximal portion of the left anterior descending artery).



7
8
9
10

1 **Figure 3**

2


3 Cardiac troponin I (cTnI) and cardiac troponin T (cTnT) concentrations in subjects assessed by

4 coronary computed tomography angiography (n=118). Green columns represent subjects

5 without coronary artery obstruction (n=109). Blue bars represent subjects with obstructive

6 coronary artery disease (CAD, n=9). The dotted horizontal line represents the 99th percentile

7 of each assay.



8

9

10


11

1

2 **Figure 4**

3 Receiver operating characteristic (ROC) curves for predicting obstructive CAD (n=9) in a
4 total of 118 subjects assessed by coronary computed tomography angiography. The two
5 subjects with myocardial bridging were excluded from this analysis; cTnI = cardiac troponin
6 I, cTnT = cardiac troponin T.

7



8
9
10
11

	AUC	95 % CI	p-value
cTnI baseline	0.48	0.29-0.66	0.80
cTnI +3h	0.65	0.45-0.95	0.14
cTnI +24h	0.79	0.61-0.96	0.005
cTnT baseline	0.56	0.38-0.73	0.57
cTnT +3h	0.57	0.36-0.77	0.10
cTnT +24h	0.82	0.70-0.94	0.002

12

1

2 **Table 1**

3 Baseline characteristics of subjects included in the study. P-value signifies differences
 4 between the High-cTnI group and the Reference group. The two subjects with myocardial
 5 bridging in the High-cTnI group were not included.

	High-cTnI group (n=78)	Reference group (n=40)	p-value
Age, years	44.6±10.8	45.8±10.8	0.67
Males, %	57 (73.1%)	31 (77.5%)	0.60
BMI, kg/m ²	25.0 (23.4-26.9)	25.0 (24.1-30.1)	0.60
Body weight, kg	81.8 (72.6-90.0)	80.6 (71.9-86.6)	0.81
Waist circumference, cm	85.0 (80-92)	84.0 (79-90)	0.71
Systolic blood pressure, mmHg	142.0 (127.5-152.0)	135.5 (124-145)	0.12
Diastolic blood pressure, mmHg	81.0 (74-88)	79.3 (73-79)	0.30
Resting HR, beats/min	58.0 (53.0-66.5)	57.5 (53.0-67.0)	0.86
Current smokers, n (%)	1 (1.3%)	0 (0)	1.00
Framingham risk score, % [*]	1 (0-5)	1 (0-5)	0.78
MET hours per week [†]	48.2 (31.7-83.0)	65.2 (44.6-89.3)	0.037
Number of races past 5 y, n	5 (2-10)	13 (5-30)	<0.001
Self-reported maximal HR, bpm	190 (184.5-195.5)	185 (177.5-190.0)	0.10
Race performance			
Race duration, h	3.7 (3.3-4.0)	3.5 (3.3-4.0)	0.70
Maximal HR during race, bpm	183.1±12.2	179.3±13.0	0.12
Maximal HR of estimated maximal HR, %	100.8 (98.7-107.6)	100.4 (97.1-104.8)	0.30
Mean HR during race, bpm	164.0 (156.0-168.0)	158.5 (150.0-165.3)	0.06
Mean HR of estimated maximal HR, %	90.8 (88.0-93.4)	88.7 (85.5-92.8)	0.13
Blood samples at baseline			
cTnI, ng/L [‡]	3.8 (1.8-8.6)	1.7 (1.6-2.9)	0.001

cTnT, ng/L [§]	3.8 (3.0-5.5)	3.0 (3.0-3.1)	<0.001
BNP, pg/mL	13.1 (10.0-21.0)	12.6 (10.0-21.0)	0.60
CRP, mg/L	0.7 (0.4-1.1)	0.7 (0.4-1.5)	0.16
Creatinine, umol/L	82.8 ± 13.5	82.2 ± 11.7	0.63
eGFR, mL/min/1.73m ²	92.8 ± 14.6	93.5 ± 12.5	0.76
LDL, mmol/L	3.1 (2.6-4.1)	3.0 (2.3-3.5)	0.07
HDL, mmol/L	1.5 (1.3-1.8)	1.5 (1.3-1.8)	0.93
Hemoglobin, g/dL	14.3 ± 1.0	14.4 ± 0.8	0.76

1 * Framingham risk score: 10-year risk of death or myocardial infarction.

2 † MET = Metabolic equivalents (3.5 ml O²/kg/min). Estimated by IPAQ-SF

3 ‡ 27.5 % had cTnI values ≤ 1.6 ng/L (limit of detection)

4 § 49.2 % had cTnT values ≤ 3.0 ng/L (limit of blank)

5 BMI = body mass index, HR = heart rate, cTnI = cardiac troponin I, cTnT = cardiac troponin T, BNP = B-type
6 natriuretic peptide, CRP = C-reactive protein, eGFR = estimated glomerular filtration rate, LDL = low-density
7 lipoproteins, HDL = high-density lipoproteins.

8

Table 2

Individual characteristics of the nine subjects with obstructive CAD and two with myocardial bridging.

	Age (years)	Gender	Race duration (h)	Framingham risk score (%)	cTnI baseline (ng/L)	cTnI +3hr (ng/L)	cTnI +24hr (ng/L)	High-cTnI group/ Reference group	Findings on angiography
Subject A	27	M	3.4	0	4.7	1002	110	High-cTnI	Myocardial bridging LAD
Subject B	55	F	4.9	1	7.6	443	181	High-cTnI	Myocardial bridging LAD, diffuse CAD
Subject C	62	M	3.4	10	1.7	28	8	Reference	Obstructive lesion LAD (FFR 0.78)
Subject D	42	M	4	1	1.6	260	169	High-cTnI	Obstructive lesion RCA (80%), CAD also in LAD
Subject E	69	M	4.9	20	2.8	999	269	High-cTnI	Obstructive lesions (80-90%) in all major vessels
Subject F	58	M	3.5	8	17.4	5026	7919	High-cTnI	Obstructive lesions in LAD (80%) and diffuse CAD
Subject G	58	M	3.5	8	7.2	269	196	High-cTnI	Obstructive lesion 1. obtuse marginal (90%), diffuse CAD
Subject H	47	M	3.8	2	2.8	206	102	High-cTnI	Obstructive lesion RCA (80%), diffuse CAD
Subject I	66	F	4.9	5	1.6	263	41	High-cTnI	Obstructive lesion LAD (90%), diffuse RCA
Subject J	57	M	4	10	1.7	200	137	High-cTnI	Obstructive lesion LAD (70%), diffuse CAD
Subject K	50	M	4.1	3	4.9	545	151	High-cTnI	Obstructive lesion 2.diagonal (80%), diffuse CAD

cTnI = cardiac troponin I, M = male, LAD = Left anterior descending artery, F = female, CAD = Coronary artery disease, FFR = Fractional flow reserve, RCA = Right coronary artery.

